US2005143289A1PendingUtilityA1
Botulinum toxin pharmaceutical composition
Est. expiryFeb 8, 2020(expired)· nominal 20-yr term from priority
Inventors:Terrence J. Hunt
A61K 9/0019A61K 9/19A61K 47/36A61K 38/4893A61K 47/183A61P 21/00Y02A50/30
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising a botulinum toxin and a recombinant albumin, suitable for therapeutic administration to a human patient, and methods for treating patients with various diseases and afflictions with the formulation.
Claims
exact text as granted — not AI-modified1 - 19 . (canceled)
20 . A pharmaceutical composition comprising a botulinum toxin type A complex with a molecular weight of about 300 kD.
21 . A pharmaceutical composition comprising a botulinum toxin type A complex with a molecular weight of about 300 kD, wherein the pharmaceutical composition is substantially free of non-300 kD botulinum toxin type A complexes.
22 . The pharmaceutical composition of claim 21 , wherein the pharmaceutical composition is substantially free of about 900 kD and about 500 kD botulinum toxin complexes.
23 . The pharmaceutical composition of claim 22 , wherein the pharmaceutical composition is essentially free of about 900 kD and about 500 kD botulinum toxin complexes.
24 . The pharmaceutical composition of claim 23 , wherein the pharmaceutical composition is entirely free of about 900 kD and about 500 kD botulinum toxin complexes.
25 . A pharmaceutical composition consisting essentially of botulinum toxin type A complex with a molecular weight of about 300 kD.
26 . A pharmaceutical composition consisting of a botulinum toxin type A complex with a molecular weight of about 300 kD.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.